Recombinant Human Cytochrome P450 7A1 (CYP7A1)

^{In
Stock}

貨號：

CSB-EP006460HU(A4)
說明書：

MSDS Datasheet
規格：

￥1836
圖片：
(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

純度：

Greater than 85% as determined by SDS-PAGE.
基因名：

CYP7A1
Uniprot No.：

P22680
種屬：

Homo sapiens (Human)
蛋白長度：

Full Length
來源：

E.coli
分子量：

61.7 kDa
表達區域：

1-504aa
氨基酸序列

MMTTSLIWGIAIAACCCLWLILGIRRRQTGEPPLENGLIPYLGCALQFGANPLEFLRANQRKHGHVFTCKLMGKYVHFITNPLSYHKVLCHGKYFDWKKFHFATSAKAFGHRSIDPMDGNTTENINDTFIKTLQGHALNSLTESMMENLQRIMRPPVSSNSKTAAWVTEGMYSFCYRVMFEAGYLTIFGRDLTRRDTQKAHILNNLDNFKQFDKVFPALVAGLPIHMFRTAHNAREKLAESLRHENLQKRESISELISLRMFLNDTLSTFDDLEKAKTHLVVLWASQANTIPATFWSLFQMIRNPEAMKAATEEVKRTLENAGQKVSLEGNPICLSQAELNDLPVLDSIIKESLRLSSASLNIRTAKEDFTLHLEDGSYNIRKDDIIALYPQLMHLDPEIYPDPLTFKYDRYLDENGKTKTTFYCNGLKLKYYYMPFGSGATICPGRLFAIHEIKQFLILMLSYFELELIEGQAKCPPLDQSRAGLGILPPLNDIEFKYKFKHL
Note: The complete sequence may include tag sequence, target protein sequence, linker sequence and extra sequence that is translated with the protein sequence for the purpose(s) of secretion, stability, solubility, etc.
If the exact amino acid sequence of this recombinant protein is critical to your application, please explicitly request the full and complete sequence of this protein before ordering.
蛋白標簽：

N-terminal 6xHis-tagged
產品提供形式：

Liquid or Lyophilized powder Warning: in_array() expects parameter 2 to be array, null given in /www/web/cusabio_cn/public_html/caches/caches_template/default/content/show_product_protein.php on line 662
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
緩沖液：

If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose.
復溶：

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
儲存條件：

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
保質期：

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
貨期：

3-7 business days
注意事項：

Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA：

Please contact us to get it.

產品評價

靶點詳情

功能：

A cytochrome P450 monooxygenase involved in the metabolism of endogenous cholesterol and its oxygenated derivatives (oxysterols). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase). Functions as a critical regulatory enzyme of bile acid biosynthesis and cholesterol homeostasis. Catalyzes the hydroxylation of carbon hydrogen bond at 7-alpha position of cholesterol, a rate-limiting step in cholesterol catabolism and bile acid biosynthesis. 7-alpha hydroxylates several oxysterols, including 4beta-hydroxycholesterol and 24-hydroxycholesterol. Catalyzes the oxidation of the 7,8 double bond of 7-dehydrocholesterol and lathosterol with direct and predominant formation of the 7-keto derivatives.
基因功能參考文獻：
1. miR-17 is a novel regulator of CYP7A1 signaling in hepatic lipid metabolism, by which miR-17 may mediate hepatosteatosis. PMID: 29721023
2. Rev-erbalpha regulates Cyp7a1 and cholesterol metabolism through its repression of the Lrh-1 receptor. PMID: 29237721
3. The analysis of the relationship of polymorphic variants CYP7A1 to lipid metabolic disturbances makes it possible to consider the AA homozygous genotype of variant mutation CYP7A1 rs 38088607 as protective against Dyslipidemia. PMID: 29171472
4. Genetic polymorphisms of CYP7A1 may be associated with susceptibility to anti-tuberculosis drug-induced hepatotoxicity in the Chinese population PMID: 27155186
5. The pronounced TC reduction in G allele carriers of rs3808607 observed in the previous study may be due to enhanced bile acid synthesis in response to high-viscosity beta-glucan consumption in those individuals. PMID: 29115200
6. Current studies suggest that increased Cyp7a1 expression and bile acid synthesis ameliorate hepatic inflammation through activation of FXR PMID: 27534992
7. This study provides evidence that individuals carrying the G allele of CYP7A1 single nucleotide polymorphism are more responsive to high molecular weight beta-glucan's effect of lowering circulating cholesterol concentrations than individuals homozygous for the T allele. PMID: 26936139
8. Genetic variations in ABCG5, CYP7A1, and DHCR7 may contribute to differing responses of serum cholesterol to dairy intake among healthy adults. PMID: 27052530
9. The promoter polymorphism of the CYP7A1 gene has a pronounced impact on diurnal variation in CYP7A1 activity. PMID: 27106353
10. The finding that overexpression of HIF-1alpha increased the activity of the CYP7A1 promoter suggested that hypoxia decreased the expression of CYP7A1 in a HIF-1-independent manner. PMID: 26521940
11. Macrophage cholesterol efflux in patients with type II diabetes mellitus was significantly reduced, and that this reduction was associated with the down-regulation of CYP7A1 expression. PMID: 26345803
12. CYP7A1 and APOE isoform are associated with the extent of reduction in circulating LDL cholesterol in response to plant sterols consumption. PMID: 26333513
13. The CYP7A1 rs7833904 polymorphism may modify the risk of CAD. PMID: 25944972
14. The CYP7A1 crystallographic models identify residues involved in cholest-4-en-3-one binding. PMID: 24927729
15. genetic polymorphism is associated with the total cholesterol level and the lipid-lowering efficacy of statin treatment. [meta-analysis] PMID: 25499945
16. we identified for the first time a significant association of the A-204C polymorphism of the CYP7A1 gene and development of tuberculosis in a Moroccan population PMID: 25360185
17. The CYP7A1 -204A>C polymorphism is significantly associated with serum lipid levels in Asian population, but not gallbladder stone disease. [Meta-analysis] PMID: 25103562
18. Cyp7a1 is a direct Thyroid hormone receptor (TR) target gene that responds to physiologic TR levels through a set of distinct response elements in its promoter. PMID: 24582860
19. Activation of the VDR represses hepatic SHP to increase levels of CYP7A1 and reduce cholesterol. PMID: 24365583
20. Two known single nucleotide polymorphisms were identified in the 5'-UTR of CYP7A1 and both were associated with neuromyelitis optica but not with Multiple sclerosis. PMID: 23740208
21. Genetic variants of CYP7A1 and its transcriptional activators (HNF4A and PPARGC1A) may activate bile acid synthesis, resulting in the accumulation of bile acids in hepatocytes leading primary biliary cirrhosis progression. PMID: 23354620
22. Prox1 interacts with LSD1 to recruit the repressive LSD1/NuRD complex to CYP7A1 promoter and co-represses transcription through epigenetic mechanisms. PMID: 23626788
23. A variant of COUP-TFII downregulates the function of COUP-TFII by inhibiting its binding to DNA, decreasing Cyp7a1 expression. PMID: 23458092
24. HNF4alpha and LRH-1 promote active transcription histone marks on the Cyp7a1 promoter that are reversed by FGF19 in a SHP-dependent manner PMID: 23038264
25. Liver X receptor alpha is required for induction of trascription of CYP7A1 in response to resveratrol. PMID: 22607622
26. these data suggest that FGF7 is a novel regulator of CYP7A1 expression in hepatocytes and may prevent hepatocytes from accumulating toxic bile acids during liver injury and fibrosis. PMID: 22713451
27. gender, but not SLCO1B1 or CYP7A1 polymorphism, has a major effect on the fasting plasma concentrations of individual bile acids PMID: 21902813
28. CYP7A1 polymorphisms are associated with colorectal adenoma. PMID: 22058145
29. The main enzyme regulating bile acids biosynthesis is CYP7A1 (7alpha-cholesterol hydroxylase). [review] PMID: 22235657
30. 7-dehydrocholesterol (the immediate precursor of cholesterol) is oxidized by P450 7A1 to 7-ketocholesterol. PMID: 21813643
31. The frequencies of rs3808607 alleles in the CYP7A1 gene differed significantly between obese hypertensive and normotensive men. PMID: 21346769
32. Results suggest that promoter -204A > C variant is associated with enhanced CYP7A1 activity. PMID: 20884100
33. Cytochrome P450 7A1 cholesterol 7alpha-hydroxylation: individual reaction steps in the catalytic cycle and rate-limiting ferric iron reduction. PMID: 21147774
34. The mRNA expression levels of sodium taurocholate cotransporting polypeptide, bile salt export pump, and hepatic cholesterol 7alpha-hydroxylase were significantly higher in the primary biliary cirrhosis patients than in the controls. PMID: 20857261
35. These results demonstrate that no association exists between apoB-100, apoE, and CYP7A1 polymorphisms and cholelithiasis in a Mexican population. PMID: 20872969
36. study found glucose positively regulated hepatocyte CYP7A1 gene & bile acid synthesis; this glucose-mediated induction of CYP7A1 transcription may be mediated by both AMPK-dependent pathway & epigenetic regulation of CYP7A1 chromatin structure PMID: 19965590
37. miR-122a and miR-422a may destabilize CYP7A1 mRNA to inhibit CYP7A1 expression. PMID: 20351063
38. insulin is involved in the regulation of diurnal variation of CYP7A1 activity in humans PMID: 19537927
39. Statistical analyses revealed that a common promoter SNP in CYP7A1 has a protective/gene dose-dependent effect on the risk of NMO. PMID: 19850125
40. mechanism for gallbladder cancer susceptibility by CYP7A1 haplotype appears to be independent of gallstone pathway and is believed to involve genotoxicity resulting from subnormal bile acid production PMID: 20005541
41. The study provides evidence that -278A>C polymorphism in the CYP7A1 gene can modify triglyceride concentrations in response to a reduced fat diet in a dyslipidemic male population. PMID: 19448895
42. CYP7A1 regulates the pathway through which cholesterol is converted into bile acids. PMID: 11907135
43. regulation of CYP7A1 and CYP27A1 in human liver PMID: 12011083
44. Human CYP7A1 deficiency: progress and enigmas. Review. PMID: 12093884
45. New metabolic disorder presenting with hyperlipidemia caused by a homozygous deletion mutation in CYP7A1. PMID: 12093894
46. data suggest that the lack of an LXR element in the region from -56 to -49 of the human CYP7A1 promoter may account for some of the differences in response to diets between humans and rodents PMID: 12202481
47. characterization of the coordinated regulation of cholesterol metabolism in human liver; regulation of its mRNA in liver PMID: 12213890
48. Data reveal a fundamental difference in the regulation of CYP7A1 in rodent and human hepatocytes. PMID: 12554795
49. demonstrated that FGF-19, acting as an FXR-induced signaling molecule, represses expression of the CYP7A1 gene; this signaling cascade defines a novel mechanism for feedback repression of bile acid biosynthesis PMID: 12815072
50. bile acids suppress transcription of the gene (CYP7A1) encoding cholesterol 7alpha-hydroxylase, the rate-limiting enzyme in bile acid biosynthesis PMID: 12865425
顯示更多

收起更多
亞細胞定位：

Endoplasmic reticulum membrane; Single-pass membrane protein. Microsome membrane; Single-pass membrane protein.
蛋白家族：

Cytochrome P450 family
組織特異性：

Detected in liver.
數據庫鏈接：

HGNC: 2651

OMIM: 118455

KEGG: hsa:1581

STRING: 9606.ENSP00000301645

UniGene: Hs.1644